PDCD1LG2 and glioma: Correspondingly, Siglec15 could potentially interact with immune-related checkpoints, including PD1, PDL1, PDL2 and CD276 (B7-H3), implying a pivotal immunoregulatory role of Siglec15 in the glioma immune microenvironment (Figure 6B).